ReviewFrontiers in immunology2026
Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory memory refers to functional changes retained by a tissue after an inflammatory episode that allow faster or stronger responses to subsequent challenges. It encompasses epigenetic memory in epithelial and stem cells, trained immunity, and tissue-resident memory T cells. Rosacea is a chronic inflammatory skin disease characterized by recurrent flushing, persistent erythema, and papulopustular lesions, and relapse after treatment cessation is common; the mechanisms that drive recurrence remain unclear. In this hypothesis-generating critical review, we use inflammatory memory as an integrative framework and examine evidence consistent with inflammatory memory in rosacea, including the Toll-like receptor 2/kallikrein-related peptidase 5/cathelicidin antimicrobial peptide (LL-37) positive feedback axis, mast-cell-mediated amplification, neuroimmune amplification, and an interleukin-1β-centered persistent inflammatory program. We draw on mechanistic evidence from psoriasis and atopic dermatitis related to tissue-resident memory T cells, epithelial memory, and trained immunity, while explicitly separating established rosacea-specific observations from indirect cross-disease parallels and speculative claims. A multilayer memory network model is proposed in which repeated triggers write memory and lower the relapse threshold; disease modification is then discussed as a candidate therapeutic goal, together with potential strategies and testable hypotheses. Direct molecular evidence for inflammatory memory in rosacea is still lacking, alternative mechanisms remain plausible, and disease modification should be viewed as a perspective rather than an established endpoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.